Allen, Christopher M., Feng, Jenny J., Willis, Mark D. ![]() ![]() |
Preview |
PDF
- Accepted Post-Print Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (108kB) | Preview |
Official URL: http://dx.doi.org/10.1016/j.msard.2019.101412
Abstract
• Alemtuzumab has been associated with stroke and cervicocephalic dissections. • Monitoring blood pressure is currently recommended by the EMA. • Monitoring blood pressure is not useful in predicting these rare side effects.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) |
Publisher: | Elsevier |
ISSN: | 2211-0348 |
Date of First Compliant Deposit: | 26 March 2020 |
Date of Acceptance: | 25 September 2019 |
Last Modified: | 24 Nov 2024 12:00 |
URI: | https://orca.cardiff.ac.uk/id/eprint/130591 |
Citation Data
Cited 25 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |